癌症研究中的CDK9抑制剂
CDK9 inhibitors in cancer research.
作者信息
Huang Zhi, Wang Tianqi, Wang Cheng, Fan Yan
机构信息
Department of Medicinal Chemistry, School of Medicine, Nankai University 94 Weijin Road Tianjin 300071 China
Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences Hefei 230031 China.
出版信息
RSC Med Chem. 2022 Apr 20;13(6):688-710. doi: 10.1039/d2md00040g. eCollection 2022 Jun 22.
Abstract
Cyclin dependent kinase 9 (CDK9) plays an essential role in regulating transcriptional elongation. Aberrations in CDK9 activity have been observed in various cancers, which make CDK9 an attractive therapeutic target for cancers. This led to an intensive development of small-molecule CDK9 inhibitors or new emerging strategies, such as proteolysis targeting chimeras (PROTACs). Here, we review the CDK9 modulators in cancer not only for research purposes, but also for therapeutic applications.
摘要
细胞周期蛋白依赖性激酶9（CDK9）在调节转录延伸中起关键作用。在多种癌症中均观察到CDK9活性异常，这使得CDK9成为极具吸引力的癌症治疗靶点。这促使了小分子CDK9抑制剂或新出现的策略（如靶向嵌合体的蛋白酶体降解技术，PROTACs）的深入研发。在此，我们综述了癌症中的CDK9调节剂，不仅用于研究目的，也用于治疗应用。
相似文献
1
CDK9 inhibitors in cancer research.癌症研究中的CDK9抑制剂
RSC Med Chem. 2022 Apr 20;13(6):688-710. doi: 10.1039/d2md00040g. eCollection 2022 Jun 22.
2
Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.CDK9 抑制剂的生物学和药物化学研究进展：最新综述。
J Med Chem. 2020 Nov 25;63(22):13228-13257. doi: 10.1021/acs.jmedchem.0c00744. Epub 2020 Sep 17.
3
Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity.基于白杨素的 CDK9 PROTACs 的发现及其抗肿瘤活性。
Bioorg Chem. 2018 Dec;81:373-381. doi: 10.1016/j.bioorg.2018.08.028. Epub 2018 Aug 30.
4
Molecular Insights on Selective and Specific Inhibitors of Cyclin Dependent Kinase 9 Enzyme (CDK9) for the Purpose of Cancer Therapy.用于癌症治疗的细胞周期蛋白依赖性激酶9（CDK9）选择性和特异性抑制剂的分子见解
Anticancer Agents Med Chem. 2023;23(4):383-403. doi: 10.2174/1871520622666220615125826.
5
Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC).通过蛋白酶靶向嵌合体（PROTAC）对CDK9进行化学诱导降解
Chem Commun (Camb). 2017 Jul 4;53(54):7577-7580. doi: 10.1039/c7cc03879h.
6
CDK9 inhibitors for the treatment of solid tumors.CDK9 抑制剂治疗实体瘤。
Biochem Pharmacol. 2024 Nov;229:116470. doi: 10.1016/j.bcp.2024.116470. Epub 2024 Aug 8.
7
Cyclin-dependent kinase 9 (Cdk9) of fission yeast is activated by the CDK-activating kinase Csk1, overlaps functionally with the TFIIH-associated kinase Mcs6, and associates with the mRNA cap methyltransferase Pcm1 in vivo.裂殖酵母的细胞周期蛋白依赖性激酶9（Cdk9）由细胞周期蛋白依赖性激酶激活激酶Csk1激活，在功能上与TFIIH相关激酶Mcs6重叠，并在体内与mRNA帽甲基转移酶Pcm1相关联。
Mol Cell Biol. 2006 Feb;26(3):777-88. doi: 10.1128/MCB.26.3.777-788.2006.
8
Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor.多发性骨髓瘤：BET 蛋白水解靶向嵌合分子与 CDK9 抑制剂联合治疗。
PLoS One. 2020 Jun 19;15(6):e0232068. doi: 10.1371/journal.pone.0232068. eCollection 2020.
9
Identification of a novel CDK9 inhibitor targeting the intramolecular hidden cavity of CDK9 induced by Tat binding.鉴定一种新型 CDK9 抑制剂，该抑制剂靶向 Tat 结合诱导的 CDK9 分子内隐藏腔。
PLoS One. 2022 Nov 15;17(11):e0277024. doi: 10.1371/journal.pone.0277024. eCollection 2022.
10
Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer.发现小分子降解物，可靶向降解 CDK9-Cyclin T1 复合物，从而抑制前列腺癌细胞中的转录成瘾。
J Med Chem. 2022 Aug 25;65(16):11034-11057. doi: 10.1021/acs.jmedchem.2c00257. Epub 2022 Aug 4.
引用本文的文献
1
Advances in KEAP1-based PROTACs as emerging therapeutic modalities: Structural basis and progress.基于KEAP1的PROTACs作为新兴治疗方式的进展：结构基础与研究进展
Redox Biol. 2025 Jul 21;85:103781. doi: 10.1016/j.redox.2025.103781.
2
Targeting MYC: Multidimensional regulation and therapeutic strategies in oncology.靶向MYC：肿瘤学中的多维调控与治疗策略
Genes Dis. 2024 Sep 16;12(4):101435. doi: 10.1016/j.gendis.2024.101435. eCollection 2025 Jul.
3
Safety and Efficacy of a Selective Inhibitor of Cyclin-dependent Kinase 9 (KB-0742) in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma.细胞周期蛋白依赖性激酶9选择性抑制剂（KB-0742）在复发性或转移性腺样囊性癌患者中的安全性和有效性
Cancer Res Commun. 2025 May 1;5(5):767-773. doi: 10.1158/2767-9764.CRC-25-0015.
4
New strategies in soft tissue sarcoma treatment.软组织肉瘤治疗的新策略。
J Hematol Oncol. 2024 Sep 2;17(1):76. doi: 10.1186/s13045-024-01580-3.
5
CDK9 Inhibition by Dinaciclib Is a Therapeutic Vulnerability in Epithelioid Hemangioendothelioma.达沙替尼抑制 CDK9 是上皮样血管内皮瘤的治疗弱点。
Clin Cancer Res. 2024 Sep 13;30(18):4179-4189. doi: 10.1158/1078-0432.CCR-24-1097.
6
OTUD1 promotes hypertensive kidney fibrosis and injury by deubiquitinating CDK9 in renal epithelial cells.OTUD1通过去泛素化肾上皮细胞中的CDK9促进高血压性肾纤维化和损伤。
Acta Pharmacol Sin. 2024 Apr;45(4):765-776. doi: 10.1038/s41401-023-01192-6. Epub 2023 Dec 18.
7
Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers.发现 KB-0742，一种强效、选择性、口服生物可利用的小分子 CDK9 抑制剂，用于 MYC 依赖性癌症。
J Med Chem. 2023 Dec 14;66(23):15629-15647. doi: 10.1021/acs.jmedchem.3c01233. Epub 2023 Nov 15.
8
Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers.靶向转录调控的 CDK9 抑制剂抑制内分泌和帕博西尼耐药 ER+ 乳腺癌的生长。
Cancer Res. 2024 Jan 2;84(1):17-25. doi: 10.1158/0008-5472.CAN-23-0650.
9
CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies.CDK9 抑制剂：血液系统恶性肿瘤治疗中有前途的联合治疗伙伴。
Oncotarget. 2023 Aug 7;14:749-752. doi: 10.18632/oncotarget.28473.
10
Targeting Transcriptional CDKs 7, 8, and 9 with Anilinopyrimidine Derivatives as Anticancer Agents: Design, Synthesis, Biological Evaluation and In Silico Studies.以蒽并嘧啶衍生物为抗癌剂靶向转录 CDK7、8 和 9：设计、合成、生物评价和计算机模拟研究。
Molecules. 2023 May 23;28(11):4271. doi: 10.3390/molecules28114271.
本文引用的文献
1
Transcriptional cyclin-dependent kinases: Potential drug targets in cancer therapy.转录周期蛋白依赖性激酶：癌症治疗中的潜在药物靶点。
Eur J Med Chem. 2022 Feb 5;229:114056. doi: 10.1016/j.ejmech.2021.114056. Epub 2021 Dec 16.
2
Harnessing Reversed Allosteric Communication: A Novel Strategy for Allosteric Drug Discovery.利用反向变构通讯：变构药物发现的新策略。
J Med Chem. 2021 Dec 23;64(24):17728-17743. doi: 10.1021/acs.jmedchem.1c01695. Epub 2021 Dec 8.
3
Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement.发现一系列 7-氮吲哚类化合物，作为瞬时靶标结合的有效且高选择性 CDK9 抑制剂。
J Med Chem. 2021 Oct 28;64(20):15189-15213. doi: 10.1021/acs.jmedchem.1c01249. Epub 2021 Oct 14.
4
Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer.发现强效和选择性 CDK9 降解剂，用于靶向三阴性乳腺癌中的转录调控。
J Med Chem. 2021 Oct 14;64(19):14822-14847. doi: 10.1021/acs.jmedchem.1c01350. Epub 2021 Sep 20.
5
Trends in kinase drug discovery: targets, indications and inhibitor design.激酶药物研发趋势：靶点、适应症和抑制剂设计。
Nat Rev Drug Discov. 2021 Nov;20(11):839-861. doi: 10.1038/s41573-021-00252-y. Epub 2021 Aug 5.
6
Activation pathway of a G protein-coupled receptor uncovers conformational intermediates as targets for allosteric drug design.G 蛋白偶联受体的激活途径揭示了构象中间态可作为变构药物设计的靶点。
Nat Commun. 2021 Aug 5;12(1):4721. doi: 10.1038/s41467-021-25020-9.
7
A rohitukine derivative IIIM-290 induces p53 dependent mitochondrial apoptosis in acute lymphoblastic leukemia cells.罗米司亭衍生物 IIIM-290 诱导急性淋巴细胞白血病细胞中 p53 依赖性线粒体凋亡。
Mol Carcinog. 2021 Oct;60(10):671-683. doi: 10.1002/mc.23332. Epub 2021 Jul 29.
8
Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.《不断优化：高活性和选择性 CDK9 抑制剂 VIP152 的发现，有望实现每周一次静脉给药，用于癌症治疗》
J Med Chem. 2021 Aug 12;64(15):11651-11674. doi: 10.1021/acs.jmedchem.1c01000. Epub 2021 Jul 15.
9
Targeting CDK9 for the Treatment of Glioblastoma.靶向CDK9治疗胶质母细胞瘤。
Cancers (Basel). 2021 Jun 18;13(12):3039. doi: 10.3390/cancers13123039.
10
Discovery of cryptic allosteric sites using reversed allosteric communication by a combined computational and experimental strategy.通过计算与实验相结合的策略利用反向变构通讯发现隐秘变构位点
Chem Sci. 2020 Nov 2;12(1):464-476. doi: 10.1039/d0sc05131d.
Zotero 插件